PleoPharma has secured a $6.5 million, three-year grant from the National Institute on Drug Abuse to support CAN-004, its ongoing pivotal Phase 3 study of PP-01 for mitigating cannabis withdrawal symptoms in adults with cannabis use disorder. The funding arrives after the clinical-stage, privately held company dosed the first CAN-004 participant in June 2026, meaning the award is supporting an active late-stage development program rather than financing preparations for a trial that has yet to begin.
That distinction makes the August 20 announcement more consequential than a conventional research-grant story. CAN-004 is targeting enrolment of about 420 adults with moderate to severe cannabis use disorder and uses a randomized, double-blind, placebo and active-controlled design, giving PleoPharma a substantially larger and more demanding efficacy test than the Phase 2b study that generated the signal supporting advancement into Phase 3. The trial is recruiting in the United States and is intended to form part of the evidence supporting a potential New Drug Application to the U.S. Food and Drug Administration.
PP-01 remains investigational, and neither the NIDA award nor the FDA Fast Track designation granted to the program in February 2025 establishes efficacy or predicts regulatory approval. What they do establish is that PleoPharma has moved its lead asset into a pivotal clinical program in a therapeutic area where a sizeable diagnosed population coexists with the absence of an FDA-approved pharmacological treatment for cannabis use disorder. That combination of unmet need, federal research support and an already recruiting Phase 3 trial creates a meaningful development opportunity, but it also concentrates the next stage of risk squarely on CAN-004.
Why does the NIDA grant matter after PleoPharma already started the CAN-004 Phase 3 trial?
The NIDA award provides $6.5 million over three years under NIH award number 1U01DA0660079-1, with PleoPharma saying the funding will support advancement of the pivotal CAN-004 program. Spread mechanically across three years, the headline value would average roughly $2.17 million annually, although actual NIH funding schedules need not follow an equal annual distribution. More importantly, PleoPharma has not disclosed the total cost of CAN-004 or enough current financial information to determine what proportion of the Phase 3 development bill will ultimately be covered by the federal award.
For a privately held biotechnology company, however, research funding of this scale can still be strategically useful because it can contribute to clinical development without representing a conventional equity financing transaction. The award therefore potentially reduces the amount of internally generated or externally raised capital that needs to be directed toward qualifying trial expenses, although it should not be interpreted as evidence that the entire pivotal program is financed through completion. PleoPharma has not publicly disclosed in the announcement whether additional capital will be required for CAN-004, manufacturing work, regulatory preparation or eventual commercialization.
The timing is also notable. PleoPharma announced the first participant dosing on June 18, while the current NIDA award was disclosed on August 20, so the program has already crossed from Phase 3 preparation into execution. The immediate operational challenge is consequently no longer whether PleoPharma can initiate the study, but whether it can recruit the planned population, maintain protocol adherence across multiple sites and produce a sufficiently convincing efficacy and safety package for regulatory review.
What does CAN-004 need to prove beyond PleoPharma’s positive Phase 2b withdrawal signal?
PleoPharma’s rationale for Phase 3 rests substantially on CAN-002, a completed randomized, double-blind, placebo-controlled Phase 2b trial involving 234 treatment-seeking adults across 22 U.S. addiction centres. The company reported that the study met its primary endpoint, with the higher PP-01 dose producing a statistically significant reduction in cannabis withdrawal symptoms compared with placebo and a dose response across the tested regimens. PleoPharma subsequently reported at the College on Problems of Drug Dependence that PP-01 was associated with a five-fold higher abstinence rate two weeks after treatment than placebo, while withdrawal reduction during the first treatment week was predictive of subsequent abstinence.
Those findings provide a rationale for confirmatory testing, but their evidentiary status remains important. The CAN-002 ClinicalTrials.gov record identifies the study as completed, although results were not posted in the registry record available during verification, while much of the detailed efficacy information has been communicated through PleoPharma announcements and scientific-meeting presentations. The pivotal program therefore needs to reproduce the withdrawal benefit in a larger population under a prespecified Phase 3 statistical framework rather than merely extend the narrative established by Phase 2.
CAN-004 is designed to enrol approximately 420 participants aged 18 to 55 with moderate to severe cannabis use disorder who are seeking to stop using cannabis. Participants receive PP-01, nabilone or placebo for 34 days, while the overall study lasts roughly 78 days and incorporates a one-week inpatient period followed by clinic and telemedicine visits. The registered primary outcomes include assessment of cannabis withdrawal scores during Days 2 through 7 for PP-01 versus placebo, together with a comparison of PP-01 and nabilone during the later Days 25 through 35 period to assess rebound.
This structure matters because a statistically successful Phase 3 program will need to demonstrate more than a transient numerical improvement shortly after cannabis discontinuation. Regulators will be interested in whether the prespecified withdrawal endpoint behaves consistently, whether the effect is sufficiently large to be clinically meaningful, whether benefits persist across relevant symptom domains, and whether the treatment introduces tolerability or discontinuation problems that could undermine real-world use. CAN-004 includes secondary assessments covering irritability, sleep and craving, giving the program an opportunity to show how an aggregate withdrawal effect translates into symptoms that matter during attempts to discontinue cannabis.
Why is the nabilone active-control arm an important part of the PP-01 Phase 3 evidence package?
PleoPharma has described PP-01 as a once-daily investigational combination incorporating titrating and tapering doses of nabilone and gabapentin, with the company positioning the regimen as acting through cannabinoid receptor and GABAergic mechanisms. The Phase 3 registry separately identifies PP-01 as a CB1 partial agonist and GABAergic modulator while including nabilone alone as an active comparator in addition to placebo.
That three-arm design could make CAN-004 more informative than a straightforward PP-01 versus placebo study. The placebo comparison addresses whether the investigational regimen produces a measurable treatment effect, while the nabilone arm can provide information relevant to the contribution of the broader PP-01 regimen and to withdrawal behaviour as treatment is tapered. The registered primary endpoint specifically includes a later PP-01 versus nabilone assessment intended to evaluate rebound, making the active comparator part of the pivotal hypothesis rather than a decorative additional arm.
The approach also reflects the broader history of cannabis-withdrawal pharmacotherapy research. Cannabinoid agonists and agents including gabapentin have previously generated signals in relatively small studies, but systematic reviews have repeatedly concluded that the evidence has been insufficient to support an approved pharmacotherapy for cannabis withdrawal or cannabis use disorder. A 50-participant randomized study of gabapentin, for example, previously reported reductions in cannabis use and withdrawal-related outcomes, while the wider literature has produced mixed results across cannabinoid and non-cannabinoid strategies.
PP-01 therefore is not entering an untouched biological field. Its opportunity depends on whether a defined combination regimen can convert earlier pharmacological observations into reproducible pivotal evidence with a treatment schedule and safety profile capable of supporting regulatory review.
How large is the cannabis use disorder treatment gap that PP-01 is attempting to address?
The epidemiological backdrop has strengthened considerably as PP-01 has advanced. The Substance Abuse and Mental Health Services Administration estimated that 20.6 million people aged 12 or older in the United States had past-year marijuana or cannabis use disorder in 2024, representing 7.1% of that population and rising from 16.7 million, or 6.0%, in 2021. The 2024 estimate included about 1.2 million adolescents, 5.5 million people aged 18 to 25 and 13.8 million adults aged 26 or older.
That prevalence does not translate automatically into a 20-million-person pharmaceutical market. PP-01 is being studied specifically in adults with moderate to severe cannabis use disorder who are seeking to discontinue use, which is considerably narrower than the total population meeting diagnostic criteria. Treatment-seeking behaviour, identification of suitable patients, clinician acceptance, payer coverage, contraindications, persistence with therapy and the eventual FDA label would all determine the commercially addressable population if PP-01 reaches the market.
The therapeutic gap is nevertheless real. NIH material continues to state that there are no FDA-approved medications for cannabis use disorder and that management relies largely on behavioural approaches and supportive care for withdrawal and craving symptoms. Cognitive behavioural therapy, motivational enhancement approaches and contingency management remain established components of treatment, so even a successful PP-01 would likely enter a care pathway that already relies heavily on psychosocial intervention rather than simply replacing an incumbent prescription medicine.
That distinction will matter commercially. Approval could establish a new pharmacological category, but uptake would still depend on whether clinicians see medication-assisted management of withdrawal as improving patients’ ability to remain engaged with cessation and behavioural treatment. Demonstrating withdrawal reduction is therefore the immediate regulatory objective, while showing how that reduction translates into sustained treatment engagement and longer-term cannabis-use outcomes could become increasingly important to clinicians and payers.
What could still stand between a positive CAN-004 result and routine use of PP-01?
The first hurdle is simply delivering a clean pivotal result. CAN-004 must recruit hundreds of treatment-seeking adults, manage a study that combines inpatient and outpatient components, maintain blinding across PP-01, nabilone and placebo arms, and capture symptom data during a period when withdrawal itself can affect sleep, mood, irritability and adherence. These characteristics make trial execution central to the quality of the final evidence package rather than a secondary operational detail.
Safety will also receive greater scrutiny as exposure expands. In CAN-002, PleoPharma reported no serious adverse events and identified headache, somnolence, fatigue, nausea and dizziness among the commonly reported mild events. That is encouraging within the disclosed Phase 2b dataset, but a larger Phase 3 population is needed to characterize tolerability more precisely and determine whether adverse effects affect discontinuation, adherence or the practical usefulness of the regimen.
Regulatory status must likewise remain in perspective. The FDA granted PP-01 Fast Track designation in February 2025 for mitigation of cannabis withdrawal syndrome in patients with cannabis use disorder, which can facilitate development interactions and potentially accelerate aspects of review. Fast Track does not mean that the FDA has established that PP-01 is effective or safe for this indication, and a successful New Drug Application would still require a sufficiently persuasive clinical, safety, manufacturing and regulatory package.
Commercial preparation represents another layer beyond clinical success. PleoPharma is privately held and has not disclosed in the NIDA announcement a commercial sales infrastructure, reimbursement strategy, prospective pricing or the complete funding requirement for bringing PP-01 from Phase 3 through a possible launch. Those issues can remain secondary while CAN-004 is recruiting, but they would become increasingly important if the pivotal study produces supportive results.
The $6.5 million NIDA grant therefore materially strengthens the development environment around PP-01 without resolving the program’s central uncertainty. PleoPharma now has federal funding, Fast Track status, a Phase 2b efficacy signal and an actively recruiting pivotal trial, while the treatment landscape still lacks an FDA-approved medication for cannabis use disorder. The next meaningful value-creating event will not be another designation or financing headline, but evidence that the 420-participant CAN-004 study can reproduce the withdrawal benefit under Phase 3 conditions and generate a safety and efficacy package strong enough to withstand regulatory scrutiny.
